ClinicalTrials.Veeva

Find clinical trials for Kidney Disease in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
Renal Insufficiency
IGA Glomerulonephritis
Renal Cell Carcinoma
Diabetes Mellitus

Kidney Disease trials near Chicago, IL, USA:

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2...

Active, not recruiting
Diabetic Kidney Disease
Drug: Placebo
Drug: INV-202

Phase 2

Inversago Pharma

Chicago, Illinois, United States of America and 71 other locations

is to evaluate the effect of tolvaptan on the need for renal replacement therapy in pediatric subjects with autosomal recessive polycystic kidney...

Enrolling
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Drug: Tolvaptan (OPC-41061)

Phase 3

Otsuka
Otsuka

Chicago, Illinois, United States and 17 other locations

Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors ...

Not yet enrolling
Kidney Failure, Chronic
Diabetic Nephropathies
Drug: Sotagliflozin
Drug: Placebo

Phase 3

Alessandro Doria

Chicago, Illinois, United States and 18 other locations

A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...

Enrolling
Chronic Kidney Disease (CKD)
Drug: REGN5458
Drug: REGN5459

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Chicago, Illinois, United States and 7 other locations

ObjectivesTo assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV)To characterize the pharmacokinetic (PK) properties...

Enrolling
Polycystic Kidney, Autosomal Dominant
Autosomal Dominant Polycystic Kidney Disease
Drug: RGLS8429
Drug: Placebo

Phase 1

Regulus Therapeutics

Chicago, Illinois, United States and 27 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Zibotentan/Dapagliflozin
Drug: Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Chicago, Illinois, United States and 321 other locations

of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys...

Active, not recruiting
Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Biological: Renal Autologous Cell Therapy (REACT)

Phase 3

Prokidney

Chicago, Illinois, United States and 45 other locations

Locations recently updated

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: VX-147
Drug: Placebo

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

Evergreen Park, Illinois, United States and 236 other locations

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney ...

Enrolling
Autosomal Recessive Polycystic Kidney (ARPKD)
Drug: Tolvaptan Suspension
Drug: Tolvaptan Tablets

Phase 3

Otsuka
Otsuka

Chicago, Illinois, United States and 18 other locations

Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:Eva...

Active, not recruiting
Secondary Hyperparathyroidism-Chronic Kidney Disease
Drug: Doxercalciferol (GZ427397)
Drug: Calcitriol

Phase 3

Sanofi
Sanofi

Chicago, Illinois, United States and 29 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems